United States Curative Therapeutics Market 2033 | Growth Drivers, Key Players & Investment Opportunities

Market Size and Growth

The global curative therapeutics market size reached US$ 19.94 Billion in 2024 from US$ 18.34 Billion in 2023 and is expected to reach US$ 44.95 Billion by 2033, growing at a CAGR of 9.5% during the forecast period 2025-2033.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/curative-therapeutics-market?sb

Key Development:

United States: Recent Curative Therapeutics Developments

✅ In December 2025, Curative a U.S.-based health services and insurance company pivoting into value‐based care raised $150 million in Series B funding at a $1.275 billion valuation, led by Upside Vision Fund and strategic investors, to scale its zero‐deductible care model nationally.

✅ In November 2025, Curative Biotechnology Inc. announced a strategic update outlining a new path to value creation, including pursuing a sublicensing/manufacturing partnership for its degenerative eye‐disease program and adjusting its capital structure.

✅ In November 2025, Curative Biotechnology withdrew its previously planned S‐1 public offering and approved a 150:1 reverse stock split to better position the company financially and prepare for a potential OTCQB market uplisting.

✅ In November 2025, Curative Biotechnology stated it is in active negotiations with potential partners to sublicense and accelerate development of its metformin‐based therapeutic for intermediate and late‐stage age‐related macular degeneration (AMD), aiming to de‐risk and speed clinical development.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=curative-therapeutics-market

Japan: Recent Curative Therapeutics Developments

✅ In November 2025, Fujifilm launched joint research with the National Cancer Center Japan to advance innovative cancer treatment technologies, focusing on targeted nucleic‐acid delivery using proprietary cyclic peptides and antisense nucleic acids a step toward next‐gen therapeutic modalities.

✅ In October 2025, Celaid Therapeutics closed the first tranche of its Series B financing, raising over JPY 1.05 billion (USD 7.2 million) to progress its lead ex vivo expanded hematopoietic stem‐cell therapy (CLD‐001) for severe pediatric non‐malignant diseases and expand R&D collaborations.

✅ In October 2025, Hinge Bio entered a license and collaboration agreement with Kyorin Pharmaceutical to develop and commercialize HB2198 a multispecific antibody‐based therapeutic for autoimmune diseases starting with lupus marking a major cross‐border curative therapeutic partnership in Japan.

✅ In July 2025, Krystal Biotech's VYJUVEK® received regulatory approval in Japan from the Ministry of Health, Labour & Welfare for the genetic treatment of dystrophic epidermolysis bullosa (DEB), making it the first approved genetic medicine of its kind and a significant curative therapeutic milestone.

Europe: Recent Curative Therapeutics

✅ In October 2025, European biotech Trogenix secured £70 million ($95 million) in a Series A financing to accelerate development of potentially curative cancer therapies using its Odysseus® platform targeting aggressive, treatment‐resistant tumors showing strong investor interest in curative approaches.

✅ In October 2025, Trogenix's financing round drew major participation from investors including IQ Capital and Eli Lilly, underlining confidence in novel curative therapeutic platforms emerging from Europe.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/curative-therapeutics-market?sb

Key Players:

=> Gilead Sciences, Inc., Spark Therapeutics, Inc., Pfizer Inc., Amgen, Inc., Novartis Pharmaceuticals Corporation, bluebird bio, Inc. and Sarepta Therapeutics, Inc., among others.

Key Segments:

By Therapy Type

Biology-Modifying Drugs - 35% share, widely used across oncology, hematology, and rare genetic disorders.
Gene Therapies - 25% share, driving innovation for rare genetic disorders and certain oncology indications.
Cell Therapies - 20% share, applied in regenerative medicine, oncology, and cardiometabolic disorders.
Others - 20% share, including combination therapies, RNA-based therapies, and emerging biologics.

By Indication

Oncology - 30% share, largest market due to high prevalence and innovation in targeted therapies.
Rare Genetic Disorders - 15% share, growth fueled by gene therapy advancements and orphan drug initiatives.
Infectious Diseases - 10% share, focused on novel biologics and vaccines.
Hematology - 10% share, driven by biologics and cell-based therapies.
Ophthalmology - 5% share, including gene therapies and cell-based regenerative treatments.
Neurology - 10% share, addressing neurodegenerative and rare neurological disorders.
Cardiometabolic Disorders - 10% share, biologics and gene therapies targeting heart and metabolic diseases.
Others - 10% share, encompassing emerging therapeutic areas and novel indications.

By End-User

Hospitals - 40% share, primary adopters of gene and cell therapy treatments.
Specialty Clinics - 25% share, focused on targeted therapies and rare disease management.
Academic and Research Institutes - 20% share, leading clinical trials and innovative therapeutic development.
Others - 15% share, including contract research organizations, private healthcare providers, and specialty centers.

By Region

North America - 40% Share
Dominated by advanced biopharmaceutical infrastructure, gene therapy pipelines, and oncology-focused therapies.

Europe - 25% Share
Growth supported by strong research ecosystems, hospital networks, and regulatory support for advanced therapies.

Asia-Pacific - 20% Share
Rapid adoption in emerging markets, increasing access to biologics, gene, and cell therapies.

South America - 10% Share
Emerging adoption in hospitals and specialty clinics, driven by rare disease and oncology treatments.

Middle East & Africa - 5% Share
Early adoption in specialized hospitals and research-focused institutions.

FAQ

What is the current size of the Curative therapeutics Market?

A: In 2024, the Curative therapeutics Market was valued at US$ 19.94 Billion , reflecting its strong industry presence.

Q2: How large is the Curative therapeutics Market expected to be by 2033?

A: By 2033, industry forecasts suggest the Curative therapeutics Market will grow to around US$ 44.95 Billion, demonstrating significant expansion.

Q3: What is the growth rate of the Curative therapeutics Market?

A: The market is projected to expand at a compound annual growth rate (CAGR) of 9.5% during the forecast period from 2025 to 2033.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?sb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?sb

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.